The effects of diethylcarbamazine on the ultrastructure of lung cells in vivo.
The pulmonary surfactant synthesis is disturbed in experimentally induced asthma, as are the intracellular storage capacity and its physical activity. These alterations may also be present in chronic asthmatic patients, and therefore the dysfunction of the pulmonary surfactant system may play an important role in the pathophysiology of asthma. Some clinical reports have described favorable results with the use of diethylcarbamazine (DEC) in patients with bronchial asthma showing that DEC is effective in terminating acute attacks of bronchial asthma. The present study aimed to analyze the ultrastructural alterations of lung cells after treatment in vivo with diethylcarbamazine. After 12 days of treatment with DEC, when compared with control samples, type II pneumocytes showed active nuclei with abundant euchromatin and evident nucleoli, and a substantially greater number of mature secretion vesicle. On the other hand, type I pneumocytes showed no morphological alterations. After DEC treatment, lung macrophages also presented several characteristics of cellular activation such as nuclei with a prominence of euchromatin and central nucleoli as well as an abundance of early and late endossomes distributed throughout the cytoplasm. These results confirm that DEC exerts a role in the activation of important pulmonary cellular pathways, which are probably related to the clinical improvement of asthma symptoms after DEC treatment.
Florêncio
M S
MS
Departamento de Morfologia, Universidade de Pernambuco, Recife, Brazil.
Saraiva
K L A
KL
Peixoto
C A
CA
D000818:Animals; D002466:Cell Nucleolus / Q000187:drug effects / Q000648:ultrastructure; D002467:Cell Nucleus / Q000187:drug effects / Q000648:ultrastructure; D003594:Cytoplasmic Granules / Q000187:drug effects / Q000648:ultrastructure; D004049:Diethylcarbamazine / Q000494:pharmacology*; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D022041:Euchromatin / Q000648:ultrastructure; D005369:Filaricides / Q000494:pharmacology*; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D016676:Macrophages, Alveolar / Q000187:drug effects* / Q000648:ultrastructure; D051379:Mice; D011663:Pulmonary Surfactants / Q000378:metabolism*; D020545:Respiratory Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure
D022041:Euchromatin; D005369:Filaricides; D011663:Pulmonary Surfactants; D004049:Diethylcarbamazine